Association between overweight and obesity determined by body mass index and overall survival in patients with metastatic prostate cancer: a meta-analysis.

IF 3.8 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

International Journal of Obesity Pub Date : 2025-08-15 DOI:10.1038/s41366-025-01883-6

Feilun Cui, Yueshi Zhang, Ziyan Liu, Changfeng Man, Dandan Gong, Yongjing Zhou, Yu Fan

{"title":"Association between overweight and obesity determined by body mass index and overall survival in patients with metastatic prostate cancer: a meta-analysis.","authors":"Feilun Cui, Yueshi Zhang, Ziyan Liu, Changfeng Man, Dandan Gong, Yongjing Zhou, Yu Fan","doi":"10.1038/s41366-025-01883-6","DOIUrl":null,"url":null,"abstract":"Background: Studies on the association between obesity and mortality in patients with prostate cancer have yielded inconclusive findings. This meta-analysis aimed to evaluate the association between overweight/obesity determined by body mass index (BMI) and overall survival (OS) in patients with metastatic prostate cancer (mPC).Methods: A systematic search was conducted in the PubMed, Web of Science, and Embase databases until February 2025. Studies that evaluated the association between overweight/obesity and OS in patients with mPC were considered.Results: Fifteen studies reported in 13 articles, including 18,280 patients, were identified. The overall pooled adjusted HR for OS was 0.79 (95% CI 0.73-0.85) for patients with overweight/obesity versus those with normal weight. The pooled adjusted HR for OS was 0.81(95%CI 0.75-0.87) for overweight and 0.78 (95%CI 0.67-0.90) for obesity. Furthermore, the association of overweight (HR 0.78; 95% CI 0.71-0.85) and obesity (HR 0.73; 95% CI 0.59-0.90) with OS was more pronounced in patients with metastatic castration-resistant prostate cancer (mCRPC). Additionally, each 1-unit increase in BMI was associated with a 4% (95% CI 1.0-8.0%) improvement in OS.Conclusion: Patients with mPC who have overweight or obesity, as defined by BMI, are associated with improved overall survival, particularly in those with mCRPC.","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41366-025-01883-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Studies on the association between obesity and mortality in patients with prostate cancer have yielded inconclusive findings. This meta-analysis aimed to evaluate the association between overweight/obesity determined by body mass index (BMI) and overall survival (OS) in patients with metastatic prostate cancer (mPC).

Methods: A systematic search was conducted in the PubMed, Web of Science, and Embase databases until February 2025. Studies that evaluated the association between overweight/obesity and OS in patients with mPC were considered.

Results: Fifteen studies reported in 13 articles, including 18,280 patients, were identified. The overall pooled adjusted HR for OS was 0.79 (95% CI 0.73-0.85) for patients with overweight/obesity versus those with normal weight. The pooled adjusted HR for OS was 0.81(95%CI 0.75-0.87) for overweight and 0.78 (95%CI 0.67-0.90) for obesity. Furthermore, the association of overweight (HR 0.78; 95% CI 0.71-0.85) and obesity (HR 0.73; 95% CI 0.59-0.90) with OS was more pronounced in patients with metastatic castration-resistant prostate cancer (mCRPC). Additionally, each 1-unit increase in BMI was associated with a 4% (95% CI 1.0-8.0%) improvement in OS.

Conclusion: Patients with mPC who have overweight or obesity, as defined by BMI, are associated with improved overall survival, particularly in those with mCRPC.

查看原文本刊更多论文

转移性前列腺癌患者体重指数和总生存率确定的超重和肥胖之间的关系：一项荟萃分析。

背景：关于前列腺癌患者肥胖与死亡率之间关系的研究尚未得出结论性结论。本荟萃分析旨在评估转移性前列腺癌（mPC）患者体重指数（BMI）确定的超重/肥胖与总生存期（OS）之间的关系。方法：系统检索PubMed、Web of Science和Embase数据库至2025年2月。我们考虑了评估mPC患者超重/肥胖与OS之间关系的研究。结果：13篇文章共报道了15项研究，包括18280例患者。与体重正常的患者相比，超重/肥胖患者的总总校正HR为0.79 （95% CI 0.73-0.85）。超重组OS的校正总风险比为0.81(95%CI 0.75-0.87)，肥胖组OS的校正总风险比为0.78 （95%CI 0.67-0.90）。此外，超重的相关性(HR 0.78；95% CI 0.71-0.85)和肥胖(HR 0.73；95% CI 0.59-0.90)与OS在转移性去势抵抗性前列腺癌（mCRPC）患者中更为明显。此外，BMI每增加1个单位，OS改善4% （95% CI 1.0-8.0%）。结论：体重指数定义的超重或肥胖的mPC患者与总生存率的提高相关，特别是那些患有mCRPC的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Obesity 医学-内分泌学与代谢

CiteScore

10.00

自引率

2.00%

发文量

221

审稿时长

3 months

期刊介绍： The International Journal of Obesity is a multi-disciplinary forum for research describing basic, clinical and applied studies in biochemistry, physiology, genetics and nutrition, molecular, metabolic, psychological and epidemiological aspects of obesity and related disorders. We publish a range of content types including original research articles, technical reports, reviews, correspondence and brief communications that elaborate on significant advances in the field and cover topical issues.